Ignite Creation Date:
2024-05-06 @ 3:27 PM
Last Modification Date:
2024-10-26 @ 1:49 PM
Study NCT ID:
NCT04636775
Status:
RECRUITING
Last Update Posted:
2023-12-11
First Post:
2020-11-13
Brief Title:
Microbiome in Immunotherapy naïve NSCLC Patients Receiving PD-1L1 Blockade MIP_NSCLC
Sponsor:
Jun Zhang MD PhD
Organization:
University of Kansas Medical Center
Study Overview
Official Title:
Microbiome in Immunotherapy naïve NSCLC Patients Receiving PD-1L1 Blockade MIP_NSCLC
Status:
RECRUITING
Status Verified Date:
2023-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This phase IV study is hoping to determine if examining the microbiome in non-small cell lung cancer immunotherapy naive participants can predict the effectiveness of immunotherapy treatment as well as determine ahead of time adverse events and their severity In addition the investigator will look into microbiome changing modifiers
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None